You just read:

Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases

News provided by

Bioniz Therapeutics, Inc.

Jan 09, 2020, 06:00 ET